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Abstract
Background: Keratoplasty is the most effective treatment for corneal blindness, but suboptimal medical conditions and lack
of qualified medical personnel and donated cornea often prevent the performance of corneal transplantation in developing
countries. Our study aims to develop alternative treatment regimens for congenital corneal diseases of genetic mutation.
Methodology/Principal Findings: Human mesenchymal stem cells isolated from neonatal umbilical cords were transplanted
to treat thin and cloudy corneas of lumican null mice. Transplantation of umbilical mesenchymal stem cells significantly
improved corneal transparency and increased stromal thickness of lumican null mice, but human umbilical hematopoietic
stem cells failed to do the same. Further studies revealed that collagen lamellae were re-organized in corneal stroma of
lumican null mice after mesenchymal stem cell transplantation. Transplanted umbilical mesenchymal stem cells survived in
the mouse corneal stroma for more than 3 months with little or no graft rejection. In addition, these cells assumed a
keratocyte phenotype, e.g., dendritic morphology, quiescence, expression of keratocyte unique keratan sulfated keratocan
and lumican, and CD34. Moreover, umbilical mesenchymal stem cell transplantation improved host keratocyte functions,
which was verified by enhanced expression of keratocan and aldehyde dehydrogenase class 3A1 in lumican null mice.
Conclusions/Significance: Umbilical mesenchymal stem cell transplantation is a promising treatment for congenital corneal
diseases involving keratocyte dysfunction. Unlike donated corneas, umbilical mesenchymal stem cells are easily isolated,
expanded, stored, and can be quickly recovered from liquid nitrogen when a patient is in urgent need.
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Introduction
There are growing interests in the use of stem cells, e.g.,
embryonic stem cells, mesenchymal stem cells, hematopoietic stem
cells, etc. in treating human congenital diseases caused by genetic
mutation and acquired diseases [1–8]. Especially, transplantation of
mesenchymal stem cells has drawn much attention in regenerative
medicine in the past decade [9,10]. Since mesenchymal stem cells
(MSCs) are first isolated from bone marrow, these plastic adherent
cells have been identified and cultivated from many connective
tissues, e.g., umbilical cord, amniotic membrane, cartilage, adipose
tissue, and conjunctiva [11–14]. MSCs are multipotent and are
capable of differentiating into various progenitor cells that form
connective tissues such as bone, bone marrow, cartilage, adipose
tissue, etc. Thus, there have been growing interests in the application
of MSC transplantation in regenerative medicine to repair and
restore normal function of diseased and injured tissues. For example,
bone marrow MSCs have been used in treating diseases in animal
models as well as in human clinical trials in areas such as
autoimmune diseases, solid organ allograft survival, hepatic cirrhosis,
kidney diseases, neuro- and muscle-degenerative diseases, myocar-
dial infarction, and spinal cord injury [15–21]. Reports using stem
cells isolated from individuals have demonstrated that the number of
cells as well as the differentiation and proliferation potential of
MSCs decreases with the donors’ age [22,23]. Umbilical cord-
derived mesenchymal stem cells (UMSCs) from newborns are
presumably young and therefore are likely to have a more potent
proliferation and differentiation capability. Other advantages to the
use of UMSCs is that the availability of umbilical cords from
newborn babies is almost unlimited and the cells can be expanded
and stored in liquid nitrogen in a tissue bank and thawed for use.
However, the utilization of human UMSCs in treating disease is
surprisingly rare in comparison to the use of bone marrow MSCs.
Only a limited number of publications have reported on the success
of using human UMSCs to treat liver fibrosis and spinal cord injury
in animal models [24–27].
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10707Dr. Eduard Zirm performed the first corneal transplantation in
1905 and to date this technique remains the most effective way for
treating corneal blindness caused by microbial infection, mechan-
ical and chemical injuries, and congenital defects due to genetic
mutation [28]. For example, trachoma is the number one cause of
corneal scarring worldwide, particularly in developing countries
where hygiene and public health services are inadequate. In
developed countries, pseudophakic bullous keratopathy, congen-
ital hereditary corneal defect, e.g., congenital corneal stromal
dystrophy, corneal lattice dystrophy, keratoconus, etc., and
corneal injuries are frequent corneal diseases requiring corneal
transplantation [29]. In the United States, there are only enough
donated corneas suitable for transplantation for the patients in the
direst need; however, this number is expected to decrease as the
number of individuals receiving LASIK (laser in situ keratomil-
eusis) increases. Worldwide, there is a shortage of suitable corneas
for transplantation because of religious and/or regional customs.
Corneal blindness in developing countries is exacerbated by the
shortage of trained medical personnel (e.g., qualified corneal
surgeons) and adequate medical facilities to perform corneal
transplantation. Thus, many children do not receive proper
treatment leading to permanent visual impairment that can
ultimately lead to a substantial burden on both the family and
society as a whole. It should be noted that currently there is no
effective alternative procedure in lieu of keratoplasty in treating
corneal blindness. Therefore, it is necessary to develop alternative
treatment regimens to replace conventional corneal transplanta-
tion, which can be performed in the suboptimal medical
conditions found in developing countries as well as under
emergency situations, e.g., battle field, disastrous regions, earth-
quake, etc. One such alternative treatment is the transplantation of
multipotent MSCs.
Lumican and keratocan, belonging to the family of small leucine
rich proteoglycans, are the major keratan sulfate proteoglycans in
the corneal stroma, which are required for corneal transparency
[30]. Lumican null (Lum
-/-) mice manifest thin and cloudy corneas
due to disorganization of stromal extracellular collagen matrix and
down-regulated expression of keratocan [31,32]. In this study, we
used Lum
-/- mice as an experimental model to test the efficacy of
UMSCs transplantation in treating congenital corneal diseases.
Our results indicate that human UMSCs transplantation greatly
improved corneal stromal thickness and transparency in Lum
-/-
mice with little or no host graft rejection.
Results
Characteristics of UMSCs isolated from human umbilical
cord
Two populations of stem cells, UMSC and umbilical cord-
derived hematopoietic stem cells (UHSCs) were isolated from
human umbilical cord and cord blood, respectively. To charac-
terize the stem cells, flow cytometry was used to determine the
expression pattern of CD markers. The results showed that .95%
of the fibroblast-like plastic-adherent cells expressed characteristic
CD markers of mesenchymal stem cells, e.g., CD105/SH2
(endoglin), CD73/SH3 (NT5E), CD90 (Thy1), CD29 (integrin
b1), CD44 (HA receptor), CD13 (alanine aminopeptidase); and
,1% of cells were positive for hematopoietic cell CD markers,
e.g., CD45 (leukocytes), CD34 (hematopoietic stem cells), CD14
(co-receptor of TLR4 and MD-2), HLA-DR (MHC-II), and CD31
(endothelial cells) (Fig. 1A).
The plastic adherent UMSCs were multipotent and capable of
differentiation into adipocytes, osteoblasts and chondrocytes when
they were cultured in adipogenic, osteogenic, and chondrogenic
medium, respectively [27,33,34]. To demonstrate differentiation
into these cell types, staining with oil-red O, alkaline phosphatase,
and toluidine blue were performed. Oil-red O staining showed
large amounts of lipid droplets indicating induction of adipogen-
esis (Fig. 1B). Osteogenesis was confirmed by expression of
alkaline phosphatase (Fig. 1C) while the synthesis of chondroitin
sulfate verified by toluidine blue staining demonstrated induction
of chondrogenesis (Fig. 1D).
To assess the percentage of CD34 positive cells after the volume
reduction of cord blood, flow cytometry was employed to examine
the characteristics of cord blood [35]. The results showed that the
cord blood cells were positive to CD34, CD45, CD59, CD133,
and BCRP1 (Fig. 1E).
To verify the expression pattern of UMSCs and UHSCs prior to
transplantation, immunofluorescent staining was performed with
selected CD markers for MSCs and HSCs, as well as to keratocan
and lumican. The results showed that both human UMSCs and
UHSCs did not express keratocan and lumican, and UMSCs were
CD34 negative (Fig. 1F).
Corneal stromal transplantation of UMSCs increased
stromal thickness and decreased corneal haze in Lum
-/-
mice
To examine the possibility whether human UMSC transplan-
tation can be used as a treatment regimen for congenital corneal
diseases of genetic mutation, UMSCs were transplanted into the
left corneas (OS) of 6 week-old Lum
-/- mice (n=11), the right
corneas (OD) served as contra-lateral controls. In vivo confocal
microscopy with the Heidelberg Retinal Tomograph-HRTII
Rostock Cornea Module (Heidelberg Engineering GmbH, Hei-
delberg, Germany) was employed to capture through-focus/serial
images by a continuous Z-axis laser scanning of the entire corneal
stroma starting at the corneal epithelium and ending at the
endothelium, at various time points including before transplanta-
tion and 4, 8, and 12 weeks after transplantation. Five different
regions of each corneal center were scanned. Corneal stromal haze
was determined by measuring total pixel intensity of light
scattering through the 3D volume while corneal stromal thickness
was measured by calculating the axial distance from the anterior to
posterior stroma, as previously described [36]. Fig. 2A and 2B
respectively displayed 3-dimensional corneal images of a Lum
-/-
mice before and 12 weeks after transplantation. It is clear to see
that less corneal haze and thicker stroma were observed in UMSC
transplanted corneas. Through calculating corneal stromal depth
by Z-stacks from in vivo confocal microscopy, stromal thickness
significantly increased in the corneas transplanted with UMSCs as
early as 8 weeks after surgery (Fig. 2C). Although there was only
an average of a 4.1 micron increase in corneal stromal thickness,
this represents approximately a 10% increase when compared to
the full stromal thickness of un-transplanted corneas. It should be
noted that transplantation of human UHSCs failed to improve the
corneal transparency and stromal thickness in Lum
-/- mice (data
not shown).
To more closely assess the changes of stromal light-scattering,
total pixel intensity of 3-dimensional volume was divided by
stromal thickness and the average of light scattering per micron
thickness of the corneal stroma was calculated. In untransplanted
corneas, light scattering in the corneal stroma showed a slight
increase with age; in contrast, corneal light scattering decreased in
transplanted corneas, which became statistically significant after 8
weeks (Fig. 2D).
Studies have shown that increased light scattering in the
posterior stroma of Lum
-/- mice is associated with the assembly of
abnormal corneal collagen fibrils leading to increased fibril size
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transplantation on light scatting, corneal stromal volume was
divided in half and the average pixel intensity per micron thickness
of the anterior and posterior cornea calculated. The data indicate
that the scattering increases in the anterior stroma with age, and
that transplantation has a significant effect on this age-related
scattering than the original. The results revealed a significant
decrease in the anterior stroma 8 weeks after transplantation as
compared to that of untreated corneas, while stromal haze was not
significantly improved in the posterior until after 12 weeks
(Fig. 2E,F). These findings suggest that in order to rescue
severely disorganized corneal collagen as is found in the posterior
stroma of Lum
-/- mice may require longer than 12 weeks.
Transplantation of UHSCs failed to improve the transparency
and stromal thickness of Lum
-/- corneas (data not shown)
Stromal collagen of Lum
-/- mice was re-organized
through the transplantation of UMSCs
Non-linear optical imaging (NLO) of second harmonic gener-
ated signals (SHG) from collagen is a novel method for assessing
collagen matrix organization in normal and diseased corneas [38].
To determine whether the improvement of corneal transparency is
associated with a change in the organization of collagen fibers in
Lum
-/- mice after UMSCs transplantation, 5 transplanted and 2
un-transplanted corneas from Lum
-/- mice were stained with Syto
59 and subsequently examined by NLO microscopy using the
methods previously described [39]. In comparison to wild type
corneas, the images of forward-scattered SHG signals revealed that
longer, larger, and more organized collagen fibers were present in
the transplanted posterior corneal stroma compared to that of un-
transplanted corneas, albeit the structure of the collagen matrix did
not fully recover to that of wild type corneas. For example, the
wide bundles of collagen fibers that form the wide posterior
collagen lamellae in the wild type cornea were completely
disrupted in the Lum
-/- mouse (Fig. 3A). By comparison, UMSC
transplanted corneas showed a partial recovery with longer and
more intact collagen fibers compared to the Lum
-/- mice but not as
broad as in the wild type cornea. This suggests that more time or
transplantation into the posterior stroma may be required to get
full restoration of corneal transparency in these corneas. Similarly,
images from back scattered SHG signals also showed better
organized collagen lamellae in the posterior stroma of wild type
mice, which was completely disrupted in the Lum
-/- mouse
(Fig. 3B). Transplantation of UMSCs also appeared to partially
restore this organized pattern.
Taken together, our findings suggest that a xenograft of human
UMSCs into the mouse cornea was capable of improving corneal
transparency and stromal thickness in Lum
-/- mice. It is worthy to note
that the success of this therapeutic strategy may depend on several
factors: 1. improvement of cell function by UMSCs transplantation; 2.
survival of UMSCs in the new tissue environment; 3. differentiation of
UMSCs into specific cell types of the target tissue; 4. maintenance
under the same cell cycle control as the host tissue without causing
tumorigenesis. Herein, these results revealed that UMSCs transplan-
tation can improve corneal transparency and stromal thickness
through the improvement of the collagen matrix. Therefore, the
following experiments were performed to determine whether UMSCs
transplanted into Lum
-/- mice corneas survive, differentiate and
maintain cell cycle control similar to host keratocytes.
Human UMSCs assume dendritic cell morphology in the
mouse corneal stroma
Human UMSCs in suspension appear small, have a round cell
shape with a few cell processes, and have large and round nuclei
with a prominent nucleolus [40]. For tracing the morphological
changes of UMSCs in the corneal stroma, UMSCs were ex vivo
labeled with DiI or DiO prior to transplantation into the cornea
and examined by fluorescent stereomicroscopy. Initially, UMSCs
stayed at the site of injection and then gradually migrated to the
corneal periphery. Morphologically, UMSCs displayed a round
cell shape in the first week after transplantation. Three weeks later,
transplanted UMSCs were homogeneously distributed in the
cornea and concurrently underwent morphological changes to
assume a dendritic cell shape as revealed by fluorescent
stereomicroscopy (Fig. 4A). These morphological changes were
better illustrated by confocal microscopy after phalloidin staining
with the whole mount Lum
-/- mouse cornea (Fig. 4B). Z-stack
confocal images revealed that transplanted UMSCs after 5 weeks
displayed a dendritic and flat cell shape and formed a three
dimensional network of cell-cell contacts between host stromal
cells and donor cells via their extensive dendritic processes, which
is similar to those of native keratocytes (Fig. 4C).
Survival and proliferation of transplanted UMSCs in
mouse corneal stroma
Successful xenograft of human UMSCs into the mouse cornea
requires that the transplanted cells escape from host immune
rejection and are able to continue to survive in the mouse corneal
stroma. To compare the survival rates of UMSCs and UHSCs in
the corneal stroma, UMSCs and UHSCs labeled by DiI or DiO
were transplanted into the corneal stroma of Lum
-/- mice. At
different time points, the nuclei were stained with DAPI and the
number of transplanted cells was determined by counting DiI or
DiO-labeled cells in confocal Z-stack images. The results revealed
that immediately after transplantation the number of UMSCs
underwent a rapid decrease, leveling off by two weeks and of these
cells half of them survived for more than 12 weeks in the stroma.
By contrast, the number of transplanted UHSCs in recipient
corneas rapidly and continuously decreased (Fig. 5A).
A TUNEL assay was performed to examine if apoptosis may
account for the cell loss after transplantation. As shown in Figure 5B
and 5C, the rate of apoptosis after UHSCs transplantation differed
from that of UMSCs. The apoptotic rate of UMSC derived cells was
initially higher than that of transplanted UHSCs within the first
48 hours of transplantation; however, this rate markedly decreased 1
week after transplantation (Fig. 5B,C). The decreased apoptotic rate
of UMSC-derived cells was associated with a slower decrease in cell
number after 3 weeks and 5 weeks. By contrast, UHSC-derived cells
showed a marked increase in the rate of apoptosis after 1 week and
remained high for up to 5 weeks (Fig. 5B,C), which is consistent with
the continued decline in cell numbers noted earlier.
Figure 1. FACS analysis of UMSCs and UHSCs. A. UMSCs isolated from human umbilical cord were characterized by flow cytometry using CD
markers; and these plastic adherent cells were positive to CD105/SH, CD13, CD29, CD44, CD73/SH3, and CD90, and negative to CD34, CD14, CD45,
CD31, and HLA-DR (MHC-II). B. There were large amounts of lipid droplets (red) in UMSCs shown by Oil-red O staining after adipogenesis induction.
C. Under osteogenic culture conditions, UMSCs expressed alkaline phosphatase (blue). D. Toluidine blue staining revealed that UMSCs synthesized
chondroitin sulfate after the induction of chondrogenesis. E. UHSCs were positive to CD34, CD45, CD59, CD133, and BCRP1, which were identified by
flow cytometry. F. Immunofluorescent staining also revealed that UMSCs were positive to CD90, CD44, and negative to CD34, CD45; UHSCs were
positive to CD34. Neither UMSCs nor UHSCs expressed keratocan and lumican before the transplantation. Scale bars: 10 mm; Blue: DAPI.
doi:10.1371/journal.pone.0010707.g001
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-/- mice was improved by the transplantation of UMSCs. A. Before UMSC
transplantation,thereweresimilarlevelsofcornealstromallightscatteringandthicknessintheright(OD,a)andleft(OS,b)eye.Panelccontainsh i st og r a m s
oflightscatteringandstromalthickness.B. Panelaandbrepresentedthe3-dimensionalimagesofHRTexamination12weeksafterUMSCstransplantation;
and clearly, lower light scattering and increased thickness displayed in the transplanted corneal stroma (b) than that of an untransplanted cornea (a). The
histograms showed thicker and less light scattering(moretransparent) in the stroma of transplantedcorneas than those of untransplanted corneas after 12
weeks. C. Corneal stromal thickness was significantly increased in the transplanted cornea than that of the untransplanted cornea after 8 weeks. D.
Compared to the untransplanted cornea the average light scattering significantly decreased in the transplanted cornea 8 and 12 weeks after UMSC
transplantation. In untransplanted corneas, there is an increase of light scattering with age. E. The average pixel intensity per mm of light scattering in the
anterior corneal stroma significantly decreased after 8 and 12 weeks. F. The improvement of light scattering as measured by average pixel intensity in the
posterior stroma was not significantly improved until 12 weeks after transplantation. (n=11; * p,0.05;* *p,0.01; *** p,0.001).
doi:10.1371/journal.pone.0010707.g002
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response [41], which might explain why UMSCs survive in the
mouse stroma; in addition to the fact that the cornea is an immune
privileged tissue. Thus, immunofluorescent staining with anti-
CD45, anti-CD90, and anti-F4/80 antibodies were used to
determine the host immune and inflammatory response after
UMSC and UHSC transplantation. The results showed that there
were more CD45+ leukocytes, CD90+ (Thy-1 cells), and F4/80+
macrophages presented in UHSC transplanted corneas than those
transplanted with UMSCs (Fig. 6A–D), indicating that UHSC
transplantation triggered a strong host immune rejection.
It should be noted that the fluorescence intensity of individual
DiI- or DiO-labeled UMSCs appeared to decrease slightly over
time (Fig. 4B), suggesting that transplanted UMSCs proliferate.
To verify this possibility, BrdU labeling was performed 2 hours
prior to sacrifice. The corneas were then subjected to whole mount
immunostaining with an anti-BrdU antibody. As expected,
transplanted UMSCs underwent proliferation evidenced by the
presence of BrdU-positive cells within the first few weeks after
transplantation (Fig. 7A,B). The transplanted UMSCs became
quiescent (no BrdU positive UMSCs) 8 weeks after transplanta-
tion, a characteristic feature of adult corneal keratocytes.
Expression of keratocyte markers by UMSCs transplanted
into the corneal stroma
As mentioned above, one of the criteria for successful cell
therapy is that donor cells must differentiate and assume a native
(host) phenotype and express genes specific to the target cells. To
verify that UMSCs could indeed assume a keratocyte phenotype,
the synthesis of KS-lumican and KS-keratocan was determined.
We have previously generated a keratocan null (Kera
-/-) mouse,
which does not express keratocan, a cornea-specific keratan sulfate
proteoglycan, and displays a thinner corneal stroma than that of a
wild type mouse [42]. For these studies, we took advantage of
keratocan and lumican null mice whose expression of keratocan
and lumican by UMSCs could be determined by immunofluores-
cent staining and western blot analysis. Fig. 8A shows the
presence of keratocan in the corneal stroma of Kera
-/- mice
detected by rabbit anti-human keratocan antibody 5 weeks after
transplantation of UMSCs. Western blot analysis indicated that a
single 45 kD protein was detected after treatment with keratanase
and/or endo-b-galactosidase (Fig. 8B). These observations are
consistent with the notion that the newly synthesized human
keratocan expressed by transplanted UMSCs is keratan sulfate
proteoglycan. Similar results were obtained when UMSCs were
Figure 3. Improved collagen fiber organization in the corneal stroma of Lum
-/- mice 12 weeks after UMSC transplantation. A. The
SHG forward scattering images revealed that collagen fibers (cyan) were more regularly organized in the transplanted cornea (n=5) than that of the
untransplanted cornea (n=2), especially in the middle and posterior stroma; moreover, the size of collagen fibers was larger in the transplanted
cornea than that of the untransplanted cornea. B. The back scattering images showed more flattened images in the transplanted cornea and uneven
lamellae (magenta) in the untransplanted cornea. Left panels, wild type mouse cornea; middle panels, Lum
-/- cornea transplanted with UMSCs; right
panels, untransplanted Lum
-/- cornea. White arrows: UMSCs; Red: Syto59; Scale bars: 50 mm.
doi:10.1371/journal.pone.0010707.g003
Mesenchymal Stem Cell Therapy
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-/- mice (Fig. 8C,D). Immuno-
staining with anti-CD34 antibodies, a known marker of human
keratocytes [43,44], was also performed. Fig. 8E demonstrated
that transplanted human UMSCs in the stroma were CD34-
positive 5 weeks after transplantation.
Improved host keratocyte function by UMSCs
transplantation in Lum
-/- mice
Our previous studies suggest that lumican is a matrikine and plays
a pivotal role in regulating multiple cellular functions, e.g., cell
migration, cell proliferation, surviv a l ,a n dg e n ee x p r e s s i o ni na d d i t i o n
to serving as a regulator of collagen fibrillogenesis [30,45,46]. Thus, it
is likely that UMSCs transplantation into Lum
-/- corneas may
improve overall tissue function by up-regulating keratocyte specific
genes, i.e., keratocan and aldehyde dehydrogenase that are down
regulated in Lum
-/- corneas [45]. To examine this possibility, semi-
quantitative western blot analysis was employed to determine the
levels of keratocan and aldehyde dehydrogenase expression in Lum
-/-
mouse corneas 5 weeks after UMSC transplantation. Fig. 9A–D
show that keratocan and aldehyde dehydrogenase levels were
increased 2–3 folds after UMSC transplantation.
Discussion
Although penetrating keratoplasty (corneal transplantation) has
been the most successful organ transplantation, the supply of
donor corneas suitable for transplantation is diminishing because
of the increased popularity of laser refractive surgery, which leaves
the cornea unsuitable for later organ transplantation. Thus,
Figure 4. Transplanted UMSCs undergoing morphological changes resembling that of host dendritic keratocytes. A. The images of in
vivo fluorescent stereoscopy showed that DiI-labeled UMSCs (red) gathered around the area of the injection tunnel and displayed a round cell shape
within the first week following transplantation; later, the cells migrated out and became dendritic in shape. At 8 weeks, the cells were
homogeneously distributed in the whole cornea. (magnification, 2006). B. Confocal microscopy revealed that transplanted UMSCs displayed a
round-like cell shape by phalloidin staining with the whole mount cornea in the first week and afterwards the cells extended their protrusions and
displayed a flat and dendritic cell shape (Scale bars: 50 mm; Blue: nuclear stain by DAPI). C. Following Phalloidin (green) staining with the whole
mount Lum
-/- mouse corneas 5 weeks after UMSCs transplantation, confocal images revealed that DiI-labeled UMSCs displayed a dendritic and flat cell
shape and formed a three dimensional network between the host stromal cells and the donor cells via their extensive dendritic processes, which is
similar to those of host keratocytes. Scale bar: 20 mm; Blue: nuclear stain by DAPI.
doi:10.1371/journal.pone.0010707.g004
Figure 5. The apoptosis of transplanted UMSCs and UHSCs in the recipient Lum
-/- corneal stroma. A. Two weeks after transplantation, the
number of UHSCs and UMSCs decreased; afterwards, UHSCs continuously diminished and almost disappeared from the cornea after 5 weeks; however,
UMSCnumbersmaintainedatarelativeconstantlevelandmorethanhalfofUMSCssurvivedinthecornealstromaupto12weeks(n$6ineachtimepoint).
B and C. TUNEL assay revealed that a large number of UMSCs was labeled (green) in 48 hours after transplantation, thereafter, very few apoptotic UMSCs
could be detected after one week. In contrast very few apoptotic cells were seen in the UHSCs within the first 48 hours after the transplantation and the
number of apoptotic UHSCs increased after 1 week and maintained at high levels thereafter (n$4 in each time point). Scale bars: 50 mm; Blue: DAPI.
doi:10.1371/journal.pone.0010707.g005
Mesenchymal Stem Cell Therapy
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are needed. Use of keratoprostheses has achieved some success as
one of the final solutions when an ordinary keratoplasty is not
possible [47,48]. Recently, it has been demonstrated that
transplantation of human corneal stromal stem cells can improve
corneal transparency in Lum
-/- mice [49]. It should be noted
however that the number of corneal stromal stem cells that can be
obtained from human corneas is quite limited and very technically
demanding.
The present study is the first to provide the evidence
demonstrating that UMSCs transplantation improved corneal
transparency and stromal thickness in Lum
-/- mice. The observed
increase in corneal function appears to be associated with
improved organization of the collagen matrix when compared to
that of untransplanted Lum
-/- corneas. We have subsequently
provided data demonstrating that transplanted UMSCs: can
survive and escape host rejection, showing a reduced host
infiltration of immune cells; assume a keratocyte-like phenotype,
having a dendritic morphology that forms a three dimensional
network and cell-cell contacts with host stromal cells; and acquire
a unique gene expression pattern similar to that of corneal
keratocytes, e.g., synthesis of KS-keratocan and KS-lumican,
aldehyde dehydrogenase, and CD34 and became quiescent after 8
weeks.
Further studies are certainly needed to elucidate molecular and
cellular mechanisms that govern the differentiation of UMSCs
within the stroma of recipient Lum
-/- mice. For example, does the
improved organization of the collagen matrix in treated Lum
-/-
corneas require de novo synthesis of collagen or is the presence of
human lumican produced by the donor cells sufficient? Our
studies indicated that transplantation of human UHSCs elicited a
significant immune response, which coincided with the loss of
transplanted UHSCs within a few weeks of transplantation. In
contrast, transplantation of human UMSCs into mouse corneas
caused little or no host immune response. The molecular and
cellular mechanisms by which MSCs suppress the host immune
response are not known, albeit co-transplantation of MSCs has
been widely used in regenerative medicine [50,51]. Likewise, bone
marrow derived mesenchymal cells have been co-transplanted
with bone marrow cells in cancer patients and other solid organ
transplantation to reduce graft versus host reaction [52]. It has
been recently demonstrated that bone marrow MSCs produce
Figure 6. The recipient inflammatory response after UMSCs and UHSCs transplantation into Lum
-/- cornea. A. Immunostaining with
antibodies against inflammatory cells, e.g., CD45 (leukocyte), CD90 (T-Cell) and F4/80 (macrophage) demonstrated the presence of large numbers of
immune and inflammatory cells in UHSC transplanted corneas but not in UMSC transplanted corneas, indicating that UMSCs might suppress the host
immune response. B. More CD45+ leukocytes invaded UHSC-recipient corneal stroma after the transplantation and the peak of leukocyte infiltration
occurred one week after transplantation (n$5 in each time point). C. The recipient F4/80+ macrophages were present in corneas transplanted with
UMSCs and UHSCs. In contrast, more macrophages were found in corneas with UHSC transplantation than that of UMSC transplantation (n$5 in each
time point). D. The infiltration of recipient CD90+ T-cells appeared at the first week and maintained at high levels after UHSC transplantation; very
few CD90+ cells were seen after UMSCs transplantation (n$5 in each time point). Scale bars: 10 mm; Blue: DAPI.
doi:10.1371/journal.pone.0010707.g006
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-/- cornea after the transplantation. A. BrdU labeled cells were identified
by whole mount immunostaining with anti-BrdU antibody (green) and the results revealed that BrdU-labeled UMSCs (red) presented at 1 and 3 weeks
after transplantation, no BrdU-labeled cells were found in corneas 8 weeks after transplantation. B. The numbers of BrdU-labeled UMSCs decreased 2
weeks after transplantation; by eight weeks, there were no BrdU-labeled cells found in the stroma, suggesting that transplanted UMSCs became
quiescent. n=6 for each time point and condition. Scale bars: 10 mm; Blue: DAPI.
doi:10.1371/journal.pone.0010707.g007
Figure 8. The synthesis of KS-keratocan, KS-lumican, and expression of CD34 by transplanted UMSCs. A. Immunostaining with anti-
human keratocan antibody displayed that keratocan (red) was distributed surrounding the transplanted UMSCs (green) in the anterior stroma of the
Kera
-/- mouse. B. Western blot revealed that human keratocan (45 kD) was detected after enzymatic digestion to remove keratan sulfate
glycosaminoglycan (KS-GAG) in the Kera
-/- cornea transplanted with UMSCs, but not in untransplanted corneas of Kera
-/-, Lum
-/- and wild type mice.
n=5. C. Immunostaining with anti-mouse lumican antibodies (cross reacts to both human and mouse lumican) displayed that lumican (red)
presented in Lum
-/- mouse cornea after UMSC (green) transplantation. D. Western blot revealed that lumican (45 kD) was detected after enzymatic
removal of KS-GAG in Lum
-/-, Kera
-/-, and wild type mouse corneas transplanted with UMSCs, but not in the Lum
-/- mouse cornea (n=4). E.
Immunostaining revealed that transplanted human UMSCs (red) were stained by anti-CD34 (green) in Lum
-/- mouse corneas six weeks after
transplantation. Scale bars: 50 mm; Blue: DAPI.
doi:10.1371/journal.pone.0010707.g008
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then inhibits T-cell proliferation [53]. Thus, it is possible that a
similar mechanism is involved in UMSCs survival. Interestingly,
there was a high rate of UMSCs apoptosis in the first 48 hours
after transplantation with very low apoptosis after 1 week. We
propose that the early encounter of UMSCs with cytokines
produced by inflammatory cells causes UMSCs apoptosis shortly
after transplantation, and subsequently up-regulates the expression
of iNOS (inducible nitrous oxide synthetase and the production of
NO that in turn suppress T-cell proliferation. It should be noted,
however, the mechanism that triggers UMSC apoptosis in the
early phase of transplantation is not known. It is possible that
heterogeneity of UMSCs population may account for the
observation. Nevertheless, further studies are needed to test these
possibilities.
Taken together, our data showed that xenograft of human
UMSCs into mouse corneas did not trigger graft rejection. Thus,
allograft of human UMSCs into human corneas is likely to be
tolerated and is of great potential for being successful in treating
human corneal blindness. Therefore, cell based therapy with
umbilical mesenchymal stem cells is a promising medical
procedure to treat congenital corneal diseases involving kerato-
cytes dysfunction.
Based on the data provided, we suggest that UMSC
transplantation may be used as an alternative treatment to corneal
transplantation for genetic and acquired corneal diseases. Unlike
donated corneas, the supply of human UMSCs is almost unlimited.
They are easily isolated from umbilical cord and can be expanded
in cell culture, and can be stored by tissue banking and quickly
recovered-from liquid nitrogen in preparation for transplantation.
In addition, intrastromal injection is a simple surgical procedure
and can be performed by adequately trained medical personnel
under even suboptimal medical conditions in developing countries,
areas of natural disaster, and/or the battle field.
Materials and Methods
Isolation and culture of umbilical cord derived UMSCs
After disinfection with 75% ethanol, the fresh umbilical cord
was transferred to PBS where excess blood on the surface was
removed. After removal of blood vessels, the tissue was sliced into
very small pieces followed by treatment with 0.05% trypsin
(Gibco, Carlsbad, CA) and 300U collagenase (Stem Cell
Technologies) in alpha-MEM (Gibco) for 1 hour at 37uC. The
solid parts were filtered and the filtrate was centrifuged at 400G to
collect the cells. After removing the supernatant, the cells were
cultured in alpha-MEM supplemented with 10% fetal bovine
serum (Hyclone, Waltham, MA) in 5% CO2 in a 37uC incubator.
On the next day, non-adherent cells were removed. The medium
was changed every 3–4 days until the plastic adherent cells
reached to near confluence. At this point, the cells were harvested
with Trypsin/EDTA and subcultured at a density of 3–6610
3
cells/cm
2
According to the current regulation of the Department of
Health of Taiwan, only parent’s consent is required for the
collection of umbilical cords from the newborn baby. Such
parents’ written consent forms acknowledging tissue donation were
obtained prior to the collection of umbilical cords. In the present
studies, no human subject was involved, thereby no IRB is
required. However, the animal protocol (#Kao 05-01-11-02) for
Figure 9. Up-regulation of keratocan and ALDH3A1 was observed in the Lum
-/- mouse cornea after UMSC transplantation. Semi-
quantitative Western blot analysis was performed to determine increased synthesis of keratocan and aldehyde dehydrogenase by recipient
keratocytes in corneas transplanted with UMSCs. Panels A and B indicated that the keratocan expression level significantly increased after UMSC
transplantation compared to untransplanted corneas. Panels C and D showed that the expression of ALDH3A1 was significantly increased in Lum
-/-
mice after UMSC transplantation (n=4).
doi:10.1371/journal.pone.0010707.g009
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approved on February 11, 2008 by IACUC of the University of
Cincinnati.
Characteristics of human UMSCs by flow cytometry
Fluorescein isothiocyanate (FITC)-conjugated or phythoery-
thrin (PE)-conjugated antibodies against CD14, CD34, CD45,
CD44, CD73, CD90, CD166, HLA-ABC, HLADR (BD Biosci-
ences, San Jose, CA) and CD105 (Southern Biotech) were used.
The plastic adherent cells were detached with trypsin/EDTA in
PBS and incubated (30 min) with the antibodies. In each case,
1610
4 events were acquired and analyzed with Cell Quest
software (Becton Dickinson, Franklin Lakes, NJ).
In vitro UMSC differentiation
The plastic adherent cells were seeded at a density of 1610
5
cells/well (6-well plate) and incubated overnight. Osteogenic
differentiation was induced using the STEMPROH Osteogenesis
Differentiation Kit (Gibco). Medium was changed twice a week
over a period of 14,21 days. To visualize osteogenic differenti-
ation, cells were stained for alkaline phosphatase. Adipogenic
differentiation was induced using the STEMPROH Adipogenesis
Differentiation Kit (Gibco). Induction medium was changed every
3–4 days and cells were cultured for at least 21 days. To
demonstrate the presence of adipocytes-like cells, cells were fixed
with 10% neutral buffered 3.7% formalin for 10 min, and then
cytoplasmic inclusions of neutral lipids were stained with oil-red O
(3 mg oil red/ml 60% isopropanol) for 15 min. Chondrogenic
differentiation was induced using the STEMPROH Chondrogen-
esis Differentiation Kit (Gibco) for 14 days and toluidine blue
staining was employed to visualize proteoglycans.
Cell processing prior to transplantation
Following the thawing of UMSCs from liquid nitrogen in a
37uC water bath, UMSCs were washed by centrifugation and
resuspended in Dulbecco’s modified eagle medium (DMEM,
Invitrogen Corporation, Grand Island, New York). UMSCs were
labeled by incubation in 1:200 diluted DiO (green fluorescence) in
DMEM for 3 hours at room temperature or DiI (red fluorescence)
in DMEM for 30 min at 37uC. After washing, UMSCs were
resuspended in PBS and a10 ml of cell suspension was mixed with
an equal volume of 0.4% trypan blue to determine the total
number of viable cells using a hemacytometer. The fluorescent
intensity might decrease, if the labeled cells underwent
proliferation.
Intrastromal injection of stem cells
To determine the stromal haze and thickness, mice (n=11)
were anesthetized by intraperitoneal injection of ketamine
hydrochloride (80 mg/kg) and xylazine (10 mg/kg). The eyes
were rinsed with PBS and topically anesthetized with a drop of
proparacaine. A corneal intrastromal tunnel into the stroma was
created with a 33-gauge needle. 1610
4 cells in 2 ml PBS were
injected into each cornea. After injection, the eyes were treated
once with ophthalmic antibiotic ointment. For immunohistochem-
istry and western blot analysis, the numbers of mice used for each
condition and time point were indicated in legends of individual
figures.
Analysis of corneal stromal haze and thickness
In vivo analysis of corneal stromal thickness and haze was
performed with Heidelberg Retinal Tomograph-HRTII Rostock
Cornea Module (HRT-II, Heidelberg Engineering Inc., Germany)
according to the manufacturer’s instruction. Briefly, a drop of
GenTealH Gel (Novartis Pharmaceuticals Corp., East Hanover,
New Jersey) was applied to the tip of the HRT-II objective as
immersion fluid. Subsequently, a series of images were collected to
cover the whole stromal thickness as a continuous z-axis scan
through the entire corneal stroma at 1–3 mm increments starting
from the basal layer of corneal epithelium and ending at the
corneal endothelium (the lens of HRTII has a working distance of
77 mm). A depth intensity profile from scans was generated by
plotting the average pixel intensity per plane as a function of
corneal depth. Corneal light scattering was then measured as
previously described [54] by calculating the total pixel intensity as
measured by the area under the curve. Corneal thickness was
determined by measuring the axial distance from the anterior to
posterior cornea.
Fluorescence and non-linear optical imaging of second
harmonic generation (SHG)
Briefly, following nuclear staining with Syto 59, the corneal
button was mounted onto the slide with Mowiol medium
(Calbiochem, La Jolla, CA) and imaged using a Zeiss Axiovert
200 inverted microscope platform with an 406water immersion
objective lens (numerical aperture, 1.2). The fluorescent signal
detection from DiO and Syto 59 were obtained using 488 nm and
633 nm laser lines from the argon and red He-Ne lasers,
respectively. Emitted light was detected using a 500 nm to
550 nm and 650 LP filters for green and Syto 59, respectively.
Non-linear optical imaging of second harmonic generated signals
(SHG) of collagen organization was performed using mode-locked
titanium (MaiTai; Spectra-Physics Lasers Division, Mountain
View, CA). The SHG forward-scattered signals were collected
using a 0.8 NA condenser lens with a narrow band-pass filter
(400/50) placed in front of the transmission light detector.
Backward scattered SHG signals were detected with the Meta
detector on the Zeiss LSM510 confocal microscope.
BrdU administration and tissue preparation for
morphology
Two hours prior to euthanasia the mice (n=16) were given an
i.p. injection of 80 mg/kg BrdU (Sigma) in PBS. Following
euthanasia and the eyes were enucleated and fixed in 4%
paraformaldehyde in 0.1 M phosphate buffer pH 7.4 (PB).
Staining of cryosections and whole mount tissues
For conventional immunostaining, cryosections (10 mm thick-
ness) were used. For the whole mount immunostaining, corneas
were incubated with conjugated antibody in 0.3% Triton X-100
buffered solution overnight; for whole mount BrdU immunostain-
ing, the whole cornea was treated by 4N HCl for 30 min, washed
with PBS at room temperature, and then incubated with
conjugated anti-BrdU antibody in 0.3% Triton X- 100 buffered
solution overnight. After incubation, corneas were washed in
0.02% Triton X-100 in PBS for 3 to 6 hours followed by washing
in PBS overnight. Finally, the corneas were mounted on slides with
Mowiol medium for confocal laser scanning microscopy.
Western blotting
A cornea was cut into small pieces under a stereomicroscope
and suspended in 100 ml alkali extraction buffer containing 250 u/
ml Benzonase nuclease (Novagen, WI) and 1X protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO) in 50 mM Tris (NaOH)
pH 12 at 4uC overnight. After being clarified by centrifugation,
the supernatant was neutralized with 10 mM Tris/HCl (pH=6.0)
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overnight. The protein was separated on a 4–20% SDS-PAGE
mini gel and then transferred to an immobilon transfer membrane
(Millipore Corp., Bedford, MA). The membrane was subjected to
western blot analysis as described previously (45). Immune
reactivity was visualized with DAB (secondary peroxidase
conjugates) or with fluorescence imaging (secondary fluorescence
conjugates) using Odyssey Infrared Imaging System (Li-COR
Biosciences, Lincoln, Nebraska).
Apoptotic analysis
Cryosections were processed by proteinase K solution and then
fixed in 4% paraformaldehyde and then subjected to TUNEL
assay with DeadEndTM Fluorometric kit (Promega Corp,
Madison, WI) according to the manufacturer’s protocol. Briefly,
after incubation with equilibration buffer, the specimens were
incubated in a solution of Nucleotide Mix and rTdT enzyme in
equilibration buffer at 37uC; and then unincorporated fluorescein-
12-dUTP was removed by washing with PBS. The number of
green fluorescence-labeled cells in the specimen was then
determined.
Statistical analysis
Data were presented as mean 6 standard deviation (SD). Two-
side paired or non-paired student’s t-test was used to compare the
mean values of two sets of data. ANOVA tests were used to
analyze the mean values of multiple group data. Differences were
considered significant at p,0.05.
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